Patent · US Active

Treatment for multiple myeloma (MM)

US10533057B2 · kind B2 · utility

1Cited by

4References

5Claims

0Family size

Assignee

MORPHOSYS AG · DE

Inventors

Stephane Leclair · Gauting, DE
Jan Endell · Munich, DE
Stefan Härtle · Jesenwang, DE

Key dates

Filing date	May 13, 2016
Grant date	Jan 14, 2020
Priority date	—
Expiry date	Aug 27, 2036

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/21
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present disclosure relates to the treatment of multiple myeloma. Monoclonal antibody MOR202 is efficacious when administered to patient at certain dosage regimens.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.